tyrosinase peptide [clinicaltrials_resource:683f3a64cb238ae29dd3c12e44aee26a]
Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal [clinicaltrials:NCT00003229]Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery [clinicaltrials:NCT00003274]Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00003339]Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma [clinicaltrials:NCT00003362]Vaccine Therapy in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00003792]Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00005633]Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00005841]Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00006113]Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00006385]Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma [clinicaltrials:NCT00019383]Vaccine Therapy in Treating Patients With Melanoma [clinicaltrials:NCT00020358]Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery [clinicaltrials:NCT00025181]Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma [clinicaltrials:NCT00031733]Vaccine Therapy in Treating Patients With Melanoma of the Eye [clinicaltrials:NCT00036816]Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma [clinicaltrials:NCT00037037]Vaccine Therapy in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00334776]
intervention [clinicaltrials_vocabulary:intervention]
tyrosinase peptide [clinicaltrials_resource:683f3a64cb238ae29dd3c12e44aee26a]
Bio2RDF identifier
683f3a64cb238ae29dd3c12e44aee26a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:683f3a64cb238ae29dd3c12e44aee26a
intervention name [clinicaltrials_vocabulary:intervention-name]
tyrosinase peptide
identifier
clinicaltrials_resource:683f3a64cb238ae29dd3c12e44aee26a
title
tyrosinase peptide
@en
type
label
tyrosinase peptide [clinicaltrials_resource:683f3a64cb238ae29dd3c12e44aee26a]
@en